Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

Giuseppe Lombardi; Gian Luca De Salvo; Alba Ariela Brandes; Marica Eoli; Roberta Rudà; Marina Faedi; Ivan Lolli; Andrea Pace; Bruno Daniele; Francesco Pasqualetti; Simona Rizzato; Luisa Bellu; Ardi Pambuku; Miriam Farina; Giovanna Magni; Stefano Indraccolo; Marina Paola Gardiman; Riccardo Soffietti; Vittorina Zagonel

doi:10.1016/s1470-2045(18)30675-2

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(18)30675-2 ◽

2019 ◽

Vol 20 (1) ◽

pp. 110-119 ◽

Cited By ~ 51

Author(s):

Giuseppe Lombardi ◽

Gian Luca De Salvo ◽

Alba Ariela Brandes ◽

Marica Eoli ◽

Roberta Rudà ◽

...

Keyword(s):

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Randomised Controlled

Download Full-text

Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(16)30561-7 ◽

2016 ◽

Vol 17 (12) ◽

pp. 1661-1671 ◽

Cited By ~ 57

Author(s):

Joel W Neal ◽

Suzanne E Dahlberg ◽

Heather A Wakelee ◽

Seena C Aisner ◽

Michaela Bowden ◽

...

Keyword(s):

Small Cell ◽

Phase 2 ◽

Wild Type ◽

Small Cell Lung ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Third Line ◽

Randomised Controlled ◽

Third Line Treatment

Download Full-text

Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial

The Lancet Neurology ◽

10.1016/s1474-4422(16)30234-4 ◽

2016 ◽

Vol 15 (12) ◽

pp. 1228-1237 ◽

Cited By ~ 147

Author(s):

Daniel F Hanley ◽

Richard E Thompson ◽

John Muschelli ◽

Michael Rosenblum ◽

Nichol McBee ◽

...

Keyword(s):

Minimally Invasive Surgery ◽

Minimally Invasive ◽

Invasive Surgery ◽

Intracerebral Haemorrhage ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Safety and efficacy of minimally invasive surgery plus alteplase in intracerebral haemorrhage evacuation (MISTIE): a randomised, controlled, open-label, phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726858225.793557568 ◽

2019 ◽

Author(s):

Jose Biller

Keyword(s):

Minimally Invasive Surgery ◽

Minimally Invasive ◽

Invasive Surgery ◽

Intracerebral Haemorrhage ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial

The Lancet Infectious Diseases ◽

10.1016/s1473-3099(12)70264-5 ◽

2013 ◽

Vol 13 (1) ◽

pp. 27-35 ◽

Cited By ~ 187

Author(s):

Rovina Ruslami ◽

A Rizal Ganiem ◽

Sofiati Dian ◽

Lika Apriani ◽

Tri Hanggono Achmad ◽

...

Keyword(s):

Tuberculous Meningitis ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Randomised Controlled

Download Full-text

Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00286-2 ◽

2021 ◽

Author(s):

Xiaofei Zhu ◽

Yangsen Cao ◽

Wenyu Liu ◽

Xiaoping Ju ◽

Xianzhi Zhao ◽

...

Keyword(s):

Pancreatic Cancer ◽

Surgical Resection ◽

Stereotactic Body Radiotherapy ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Recurrent Pancreatic Cancer ◽

Locally Recurrent ◽

Randomised Controlled

Download Full-text

High Versus Ad Libitum Water Intake in Patients with Autosomal Dominant Polycystic Kidney Disease (DRINK): An Open Label, Randomised Controlled Phase 2 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3294762 ◽

2018 ◽

Author(s):

Ragada El-Damanawi ◽

Michael Lee ◽

Tess Harris ◽

Laura B. Mader ◽

Simon Bond ◽

...

Keyword(s):

Kidney Disease ◽

Polycystic Kidney Disease ◽

Autosomal Dominant ◽

Phase 2 ◽

Polycystic Kidney ◽

Open Label ◽

Phase 2 Trial ◽

Ad Libitum ◽

Autosomal Dominant Polycystic Kidney ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717962541.793465519 ◽

2012 ◽

Author(s):

Diederik van de Beek ◽

Matthijs Brouwer

Keyword(s):

Tuberculous Meningitis ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Randomised Controlled

Download Full-text

Faculty Opinions recommendation of Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725773204.793527325 ◽

2017 ◽

Author(s):

Katherine Fuh

Keyword(s):

Targeted Therapy ◽

Advanced Cancer ◽

Conventional Therapy ◽

Molecular Profiling ◽

Phase 2 ◽

Proof Of Concept ◽

Open Label ◽

Molecularly Targeted Therapy ◽

Phase 2 Trial ◽

Randomised Controlled

Download Full-text

Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)71200-8 ◽

2015 ◽

Vol 16 (2) ◽

pp. 221-232 ◽

Cited By ~ 96

Author(s):

Jordi Giralt ◽

Jose Trigo ◽

Sandra Nuyts ◽

Mahmut Ozsahin ◽

Krzysztof Skladowski ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text

Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)71198-2 ◽

2015 ◽

Vol 16 (2) ◽

pp. 208-220 ◽

Cited By ~ 94

Author(s):

Ricard Mesía ◽

Michael Henke ◽

Andre Fortin ◽

Heikki Minn ◽

Alejandro Cesar Yunes Ancona ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Open Label Phase ◽

Randomised Controlled

Download Full-text